-transparent.png){kind=logo}
Chagas' disease, which is caused by Trypanosoma cruzi, remains essentially incurable. Due principally to a lack of profit incentive, the pharmaceutical industry has had limited interest in developing new antichagasic drugs. Thus, a search for agents that exhibit activity against T. cruzi, although medicaments have been developed for the treatment of other diseases, seems justifiable. Responding to evidence that the principal biochemical differences between mammalian cells and African trypanosomes apply equally to T. cruzi, our evaluations were conducted. Previous work showed the effectiveness of anticancer agents against T. rhodesiense. In the present studies, 76 anticancer compounds were assessed for their ability to suppress the trypomastigotes of T. cruzi- infected mice. Five compounds were found to be active. The most effective was cycloheximide, which was more than six times as effective as the standard, nifurtimox.
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
September 1977,
Tropenmedizin und Parasitologie,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
June 1982,
Annals of tropical medicine and parasitology,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
November 2009,
Memorias do Instituto Oswaldo Cruz,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
June 2013,
ACS medicinal chemistry letters,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
January 2008,
Natural product research,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
June 2015,
Memorias do Instituto Oswaldo Cruz,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
June 1987,
The Journal of parasitology,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
January 2003,
Chronobiology international,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
January 1982,
Acta cytologica,
K E Kinnamon, and
B T Poon, and
W L Hanson, and
V B Waits
January 2017,
Combinatorial chemistry & high throughput screening,
